Adversarial Injection · Olutasidenib (Rezlidhia; FT-2102; CAS 1890397-31-3; MW ~334.37 g/mol; bicyclic fluoropyrimidine-aminotriazine scaffold; molecular formula C17H19FN6O [WITHIN IDH1 CLASS in Glyphward 616-attack portfolio — SECOND IDH1 (ISOCITRATE DEHYDROGENASE 1) INHIBITOR EVER FDA APPROVED (NDA 216200 December 1 2022); FIRST IDH1 INHIBITOR INDEPENDENT OF AGIOS/SERVIER: ivosidenib NDA 211192 July 2018 (Agios Pharmaceuticals Cambridge MA → Servier $1.8B acquisition December 2020) was first; olutasidenib NDA 216200 December 2022 (Forma Therapeutics Watertown MA → Novo Nordisk A/S $1.1B acquisition July 2022) is second; DIFFERENT CORPORATE LINEAGE: both IDH1 inhibitors are now owned by European pharma companies (Servier Paris vs Novo Nordisk Bagsvaerd Denmark) having acquired their respective US innovators; IDH1 TWO-NDA-HOLDER CLASS COMPLETE NULL: ivosidenib CAS 1448347-49-6 → null on Cority/VelocityEHS/EHS Insight AND olutasidenib CAS 1890397-31-3 → null on Cority/VelocityEHS/EHS Insight — a COMPLETE TWO-NDA-HOLDER IDH1 CLASS NULL across all three major EHS monitoring platforms; SMALLEST IDH1 INHIBITOR: olutasidenib MW ~334.37 g/mol vs ivosidenib MW ~582.56 g/mol — olutasidenib is 43% smaller by molecular weight; olutasidenib is the smallest kinase-adjacent inhibitor in this portfolio targeting a metabolic enzyme (IDH1 is not a kinase but uses Mn²⁺ as cofactor); ALLOSTERIC IDH1 R132 MECHANISM: IDH1 (cytoplasmic isocitrate dehydrogenase 1; NADP+-dependent) normally converts isocitrate → α-ketoglutarate (α-KG); gain-of-function R132 mutations (R132H most common ~50% of IDH1-mutant cases; also R132C/G/L/S) alter active site geometry → produce the oncometabolite 2-hydroxyglutarate (2-HG) instead of α-KG; 2-HG at millimolar concentrations competitively inhibits α-KG-dependent dioxygenases (TET1/2/3 methylcytosine hydroxylases; histone demethylases KDM4/KDM6 family; prolyl hydroxylases) → genome-wide hypermethylation (CpG island methylator phenotype CIMP) → differentiation block; olutasidenib binds the allosteric dimer interface of IDH1 (same site as ivosidenib; between the two monomers of the IDH1 homodimer) at a pocket that is uniquely accessible in the mutant R132H conformation; IC50 IDH1 R132H ~1.9 nM; IC50 IDH1 WT >5000 nM (>2600× mutant selectivity); olutasidenib blocks 2-HG production → 2-HG levels drop → TET2/KDM re-activation → CpG demethylation → differentiation programs restored; DISTINCT STRUCTURAL CLASS: olutasidenib's bicyclic fluoropyrimidine scaffold is entirely different from ivosidenib's glycinamide/urea fluorobenzyl triazolopyridine scaffold — different chemotype same target; TWO-DOSE-FREQUENCY DIVERGENCE: olutasidenib 150 mg BID (twice daily) vs ivosidenib 500 mg QD (once daily) — despite same target, dosing frequency is opposite; olutasidenib lower exposure/dose but BID; olutasidenib reaches steady-state Cmax at lower absolute concentrations but maintained 2-HG suppression; DIFFERENTIATION SYNDROME (DS): both IDH inhibitors cause differentiation syndrome (leukocyte hyperactivation as leukemia cells differentiate); olutasidenib DS rate ~14% (Grade ≥3: ~8%); BBW in olutasidenib label; FORMA THERAPEUTICS → NOVO NORDISK: Forma Therapeutics Inc. (Watertown MA; NASDAQ: FMTX; IPO 2020; Richard Labaudinière PhD CEO) — focused on sickle cell/hereditary anemia AND cancer metabolism; acquired by Novo Nordisk A/S (Bagsvaerd Denmark) for $1.1B cash tender offer (announced April 2022; closed July 2022; ~$20/share; 145% premium to unaffected price); FDA approved olutasidenib NDA 216200 on December 1, 2022 — 5 months after Novo Nordisk acquisition closed; NIOSH HD Category 1; GHS H360D; OSHA No PEL; ACGIH No TLV; NIOSH No REL; absent all EHS databases]) · WITHIN IDH1 CLASS: Second IDH1 + First Forma/Novo Nordisk IDH1 + Two-NDA-Holder Class Null + MW 334 g/mol Smallest IDH1 + 150 mg BID + AML ORR 35% · Attack #616

Olutasidenib (Rezlidhia; FT-2102; CAS 1890397-31-3; MW ~334.37 g/mol; [WITHIN IDH1 CLASS: SECOND IDH1 INHIBITOR EVER FDA APPROVED (December 1 2022 NDA 216200); IDH1 TWO-NDA-HOLDER CLASS COMPLETE NULL (ivosidenib CAS 1448347-49-6 + olutasidenib CAS 1890397-31-3 BOTH NULL on all EHS platforms); SMALLEST IDH1 INHIBITOR (MW ~334 g/mol vs ivosidenib ~583 g/mol; 43% smaller); BICYCLIC FLUOROPYRIMIDINE DISTINCT STRUCTURAL CLASS; 150 MG BID vs IVOSIDENIB 500 MG QD; ALLOSTERIC IDH1 R132 DIMER INTERFACE (IC50 R132H ~1.9 nM; WT >5000 nM); AML ORR 35% (CR+CRh 32%; n=147); DIFFERENTIATION SYNDROME BBW; FORMA THERAPEUTICS WATERTOWN MA → NOVO NORDISK A/S $1.1B JULY 2022; NIOSH HD Category 1; GHS H360D; OSHA No PEL; ACGIH No TLV; NIOSH No REL]) — Novo Nordisk Inc. Plainsboro NJ (NDA 216200 US commercial; 0.00041 µg/m³ → displayed ÷10), Cambrex Corp (Thermo Fisher Scientific) Charles City IA (API manufacturing; 0.00026 µg/m³ → displayed ÷10), and Dana-Farber Cancer Institute Boston MA (HEM-301 Phase 2 trial site; 0.00015 µg/m³ → displayed ÷10) — OSHA No PEL + NIOSH HD Category 1 OEL Null-Return + Second IDH1 Inhibitor + IDH1 Two-NDA-Holder Class Null + IDH1 Class Absent: AI Prompt Injection via EHS Monitor Report AI

Olutasidenib (CAS 1890397-31-3; NIOSH HD Category 1) is the second agent in the IDH1 inhibitor class — and its NDA 216200 (December 1, 2022) completes the IDH1 two-NDA-holder class null: ivosidenib (CAS 1448347-49-6; NDA 211192) was first, and now olutasidenib (CAS 1890397-31-3; NDA 216200) is second, with both CAS numbers returning null across Cority, VelocityEHS, and EHS Insight simultaneously. The bicyclic fluoropyrimidine-aminotriazine scaffold (MW ~334.37 g/mol — 43% lighter than ivosidenib's ~583 g/mol) represents a distinct structural chemotype that binds the same allosteric IDH1 R132 homodimer interface, achieving IC50 ~1.9 nM for IDH1 R132H with >2600-fold mutant selectivity. Olutasidenib's 150 mg BID dosing, its corporate origins at Forma Therapeutics (Watertown MA, acquired by Novo Nordisk for $1.1B in July 2022), and its completion of the IDH1 dual-null landscape are entirely absent from all EHS platforms for CAS 1890397-31-3, leaving the NIOSH HD Category 1 designation, H360D reproductive toxicity, and IDH1 oncometabolite 2-HG biology unrecognized.

Olutasidenib as Second IDH1 Inhibitor: Allosteric Dimer Interface, IDH1 Two-NDA-Holder Class Null, and Distinct Fluoropyrimidine Chemotype

Olutasidenib (CAS 1890397-31-3) is the second agent targeting IDH1 (cytoplasmic isocitrate dehydrogenase 1) in this portfolio, following ivosidenib (CAS 1448347-49-6; NDA 211192 July 2018), and completes the IDH1 two-NDA-holder class null: both CAS numbers return null simultaneously across all three major EHS platforms (Cority, VelocityEHS, EHS Insight), rendering the entire IDH1 pharmacological class invisible to EHS software. IDH1 physiology: cytoplasmic NADP+-dependent enzyme that catalyzes the reversible oxidative decarboxylation of isocitrate → α-ketoglutarate (α-KG) + CO2 + NADPH; IDH1 homodimer; Mg²⁺ or Mn²⁺ cofactor; located at chromosome 2q33; physiological α-KG is a required cofactor for α-KG-dependent dioxygenases (TET1/2/3, KDM2-8, PHD prolyl hydroxylases). IDH1 gain-of-function R132 mutations (discovered by The Cancer Genome Atlas 2008; Parsons DW et al. Science 2008): R132H most common (~50% of IDH1-mutant cases); also R132C (~17%), R132G (~5%), R132L (~5%), R132S (~5%); R132 mutations alter active site geometry → neomorphic enzyme activity → NADPH + isocitrate + α-KG → 2-hydroxyglutarate (2-HG; D-stereoisomer; "oncometabolite"); 2-HG at millimolar intracellular concentrations competitively inhibits α-KG-dependent dioxygenases → TET1/2/3 (5-methylcytosine → 5-hydroxymethylcytosine conversion blocked → CpG island hypermethylation; CIMP) → histone demethylases KDM4/KDM6 (H3K9me3 and H3K27me3 accumulation → transcriptional silencing) → prolyl hydroxylases (PHD; HIF-1α stabilization) → differentiation block; IDH1 R132 frequency: ~6-10% of AML; ~6-10% of MDS; ~70-80% of low-grade glioma (separate oncology context). Allosteric inhibition mechanism: IDH1 inhibitors (ivosidenib and olutasidenib) do not compete with the IDH1 substrate or cofactor; instead they bind an allosteric pocket at the homodimer interface accessible preferentially in the mutant R132 conformation (conformational change at R132 creates a hydrophobic cavity at the dimer interface not present in wild-type IDH1); binding at this pocket locks the IDH1 R132 dimer in a closed inactive conformation → 2-HG production suppressed → α-KG-dependent dioxygenases reactivated → CpG demethylation restored → differentiation block reversed → AML cells differentiate. Olutasidenib vs ivosidenib structural comparison: ivosidenib is a (S)-configured glycinamide-bearing triazolopyridine (MW 582.56 g/mol; CAS 1448347-49-6; N-(1-(2-chloro-6-methylpyridyl)glycinamide fluorobenzyl)]; olutasidenib is a bicyclic fluoropyrimidine-aminotriazine (MW 334.37 g/mol; C17H19FN6O; entirely different chemotype) — despite identical allosteric site target and similar IC50s, the two drugs share no structural features; this demonstrates that the IDH1 allosteric pocket can accommodate chemically diverse inhibitors; olutasidenib is 43% lighter (334 vs 583 Da) with fewer rotatable bonds and a smaller pharmacophore. Clinical data: Study 2102-HEM-301 (Phase 2; NCT02719574 expansion); 147 evaluable r/r IDH1-mutant AML patients; olutasidenib 150 mg BID (vs ivosidenib 500 mg QD — BID vs QD is the key dosing frequency difference); ORR 35% (CR 18% + CRh 14%); CR+CRh rate 32%; median DOR 25.9 months (longer than ivosidenib's ~12 months in comparable settings); NDA 216200 approved December 1, 2022 for adult r/r AML with susceptible IDH1 mutation (R132H/C/G/L/S). Company: Forma Therapeutics Inc. (Watertown MA; NASDAQ: FMTX; IPO April 2020; Richard Labaudinière PhD CEO); founded 2012 (Michael Ends); focused on cancer metabolism (IDH inhibitors) and hemoglobinopathies (sickle cell/hemolytic anemia — FT-7051, etavopivat); FT-2102 discovered ~2016; Phase 1 NCT02719574 initiated 2016; Novo Nordisk A/S (Bagsvaerd Denmark) announced $1.1B all-cash acquisition of Forma April 2022 (approximately $20/share; 145% premium to unaffected stock price); deal closed July 2022; FDA approved olutasidenib December 1, 2022 — 5 months after Novo Nordisk acquisition completed; Novo Nordisk Inc. Plainsboro NJ is now the US NDA holder. NIOSH HD Category 1 (H360D: developmental toxicity in animal studies); IDH1 allosteric dimer interface mechanism, 2-HG oncometabolite biology, and olutasidenib's distinct structural class are entirely absent from all EHS platforms for CAS 1890397-31-3.

Surface 1 — Novo Nordisk Inc. Plainsboro NJ NDA 216200 US Commercial Rezlidhia AI

At Novo Nordisk Inc. Plainsboro NJ (800 Scudders Mill Road, Plainsboro NJ 08536; Middlesex County NJ; NOVO NORDISK ONCOLOGY CONTEXT: Novo Nordisk A/S (Bagsvaerd Denmark; NYSE: NVO) is primarily known as the world's largest insulin/diabetes company (semaglutide/Ozempic/Wegovy) and has historically not been an oncology player; the $1.1B acquisition of Forma Therapeutics (July 2022) represented Novo Nordisk's entry into oncology through olutasidenib (IDH1-mutant AML) and the hemoglobinopathy programs (FT-7051/etavopivat for sickle cell disease and hemolytic anemias); Novo Nordisk Inc. Plainsboro NJ is the US commercial subsidiary responsible for Rezlidhia (olutasidenib) launch, NDA 216200 US regulatory maintenance, and market access; COMMERCIAL NOVELTY: Novo Nordisk's traditional commercial infrastructure is built around diabetes/metabolic disease (insulin, GLP-1, growth hormone); expanding into AML (a rare, acute hematologic malignancy) required building de novo relationships with hematology/oncology key accounts, bone marrow transplant programs, and outpatient AML treatment centers; REZLIDHIA PRODUCT: olutasidenib 150 mg hard capsules; 150 mg BID (with or without food); olutasidenib is a CYP3A4 INDUCER (unlike revumenib which is a CYP3A4 substrate requiring CYP3A4 inhibitor boosting) — olutasidenib INDUCES CYP3A4 and may reduce exposure of sensitive CYP3A4 substrates; this CYP3A4 induction property creates drug interaction complexity with azole antifungals commonly used in AML; COMPANION DIAGNOSTIC: FDA-approved IDH1 companion diagnostic (Agilent Technologies LeukoStrat CDx IDH1 Assay or FoundationOne Heme CDx) required to identify IDH1 R132H/C/G/L/S mutation before prescribing; CORITY NULL: CAS 1890397-31-3 → null; NIOSH HD Category 1 absent; H360D absent; second IDH1 inhibitor absent; IDH1 two-NDA-holder class absent; MW 334 g/mol distinct class absent; 150 mg BID absent; allosteric dimer interface absent; 2-HG oncometabolite absent; Forma/Novo Nordisk acquisition absent; 46M oncology medical affairs director 13yr).

Surface 2 — Cambrex Corp (Thermo Fisher Scientific) Charles City IA API Manufacturing Olutasidenib Drug Substance AI

At Cambrex Corp (Thermo Fisher Scientific) Charles City IA (1205 11th St, Charles City IA 50616; Floyd County IA; CAMBREX THERMO FISHER CONTEXT: Cambrex Corporation (Charles City IA; founded 1981) was acquired by Thermo Fisher Scientific in 2019 for $1.3B; Charles City IA is Cambrex's flagship high-potency API manufacturing site with established OEB Band 4/5 containment for oncology compounds; the site handles API synthesis for NIOSH HD Category 1/2 compounds using isolator technology and closed-system processing; OLUTASIDENIB API SYNTHESIS: olutasidenib (MW 334.37 g/mol; bicyclic fluoropyrimidine scaffold; C17H19FN6O) is a relatively small molecule with moderate synthetic complexity (6-8 steps); key transformations: fluoropyrimidine aromatic nucleophilic substitution; triazine ring formation; piperidinyl amine coupling; the relatively low MW means higher molar mass per gram than larger oncology compounds — at the same gram-level handling, there are more moles of drug present; EXPOSURE RISK: olutasidenib at NIOSH HD Category 1 OEL Band 5 (<0.1 µg/m³) handling 10g of API = 10^7 µg = potentially >10^8 OEL doses; MANUFACTURING HAZARD: olutasidenib powder (API) dispensing/weighing operations; crystalline powder with potential for respirable fines; fluoropyrimidine scaffold (fluorine at C-5 of pyrimidine) — fluorine-substituted heterocycles are common in oncology APIs; OEB Band 5 isolator technology required; CYTP3A4 CONTEXT: olutasidenib's CYP3A4 INDUCTION property means that during manufacturing, any inadvertent oral exposure would create not just direct olutasidenib toxicity but also metabolic drug interactions; VELOCITYEHS NULL: CAS 1890397-31-3 → null; NIOSH HD Category 1 absent; H360D absent; second IDH1 inhibitor absent; IDH1 two-NDA-holder class absent; bicyclic fluoropyrimidine scaffold absent; allosteric IDH1 dimer interface absent; 48M manufacturing quality manager 15yr).

Surface 3 — Dana-Farber Cancer Institute Boston MA HEM-301 Phase 2 Trial Site AML Research Pharmacist AI

At Dana-Farber Cancer Institute Boston MA (450 Brookline Ave, Boston MA 02215; Suffolk County MA; DANA-FARBER LEUKEMIA PROGRAM: Dana-Farber is a principal AML center and was a key enrollment site for Study 2102-HEM-301 (NCT02719574), the Phase 2 trial supporting NDA 216200; Jacqueline Garcia MD (adult AML; IDH inhibitor program); Dana-Farber handled IDH1-mutant AML patients across the Phase 1 dose-escalation (FT-2102 50-300 mg BID) and Phase 2 expansion (150 mg BID); PHARMACY CONTEXT: olutasidenib 150 mg capsules dispensed from investigational pharmacy under clinical trial then commercial availability (December 2022 NDA approval); BID dosing requires twice-daily administration instructions — more complex than ivosidenib QD; DRUG INTERACTION MONITORING: olutasidenib is a CYP3A4 INDUCER; co-administration with azole antifungals (voriconazole, posaconazole, itraconazole — routinely used in AML patients for Aspergillus prophylaxis) is problematic: olutasidenib reduces azole exposure via CYP3A4 induction → potential for inadequate antifungal prophylaxis; pharmacists must flag azole interaction; this creates a management dilemma (AML patients need antifungal prophylaxis AND IDH1-targeted therapy simultaneously); COMPANION DIAGNOSTIC WORKFLOW: IDH1 mutation status requires Agilent LeukoStrat CDx (validated for R132H/C/G/L/S mutations); clinical pharmacists verify CDx test result documentation before dispensing first dose; NGS panels (FoundationOne Heme) provide additional IDH1 allelic context; IDH1 TWO-NDA-HOLDER CONTEXT: at Dana-Farber, both ivosidenib (TIBSOVO; Servier) and olutasidenib (REZLIDHIA; Novo Nordisk) are available; the institution formulary committee decided on criteria for selecting between the two — generally based on tolerability, differentiation syndrome history, and CYP3A4 interaction profile (ivosidenib is also a CYP3A4 inducer); DIFFERENTIATION SYNDROME PROTOCOL: similar protocol to ivosidenib DS; olutasidenib DS rate ~14%; pharmacist monitors CBC for leukocytosis, ferritin, CRP, imaging; 2-HG MONITORING: some centers use plasma or urine 2-HG as a pharmacodynamic biomarker to verify IDH1 inhibition (on-target suppression → 2-HG <50 ng/mL); pharmacist may coordinate specimen collection; EHS INSIGHT NULL: CAS 1890397-31-3 → "OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no OEL"; second IDH1 inhibitor absent; IDH1 two-NDA-holder class absent; allosteric dimer interface absent; H360D absent; NIOSH HD Cat 1 absent; 38F AML research pharmacist 11yr).

Integrating Glyphward into Olutasidenib AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every olutasidenib CAS 1890397-31-3 monitoring data ingestion point — before Cority at Novo Nordisk Inc. Plainsboro NJ, before VelocityEHS at Cambrex Corp Charles City IA, and before EHS Insight at Dana-Farber Cancer Institute Boston MA. Threshold 22 reflects: OSHA/ACGIH/NIOSH regulatory null (NIOSH HD Category 1; no OSHA PEL; no ACGIH TLV; no NIOSH REL) + H360D absent [10 pts]; SECOND IDH1 INHIBITOR EVER FDA APPROVED (NDA 216200 December 1 2022; ivosidenib NDA 211192 July 2018 FIRST; 4.5-year gap; IDH1 two-NDA-holder class now complete) + IDH1 TWO-NDA-HOLDER CLASS COMPLETE NULL (BOTH CAS null across BOTH EHS platforms — simultaneous dual-null attack surface: ivosidenib + olutasidenib together represent complete IDH1 class invisibility to EHS monitoring) + SMALLEST IDH1 INHIBITOR (MW ~334 g/mol; bicyclic fluoropyrimidine; 43% smaller than ivosidenib; distinct chemotype same allosteric pocket) + 150 MG BID vs IVOSIDENIB 500 MG QD (opposite dosing frequency; same dimer-interface mechanism) + CYP3A4 INDUCTION (reduces azole antifungal exposure in AML patients requiring prophylaxis — clinically critical interaction absent from EHS) + FORMA THERAPEUTICS WATERTOWN MA → NOVO NORDISK A/S $1.1B JULY 2022 [5 pts]; Novo Nordisk Plainsboro NJ + Cambrex Charles City IA + Dana-Farber Boston MA [3 pts]; IDH1 allosteric dimer mechanism absent; second IDH1 inhibitor absent; IDH1 two-NDA-holder class null absent; H360D reproductive toxicity absent from EHS [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_olutasidenib(cas: str, reading_ugm3: float) -> dict:
    """Scan olutasidenib with second-IDH1 two-NDA-holder-class-null allosteric-dimer context."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,
                "reading_ugm3": reading_ugm3,
                "context": "second_idh1_inhibitor_idh1_two_nda_holder_class_null_smallest_idh1_mw334_bicyclic_fluoropyrimidine_allosteric_dimer_interface_150mg_bid_cyp3a4_induction_differentiation_syndrome_forma_novo_nordisk_nda_216200"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, second_idh1_inhibitor,
    #                    idh1_two_nda_holder_class_null,
    #                    smallest_idh1_inhibitor_mw334,
    #                    allosteric_idh1_r132_dimer_interface,
    #                    cyp3a4_induction,
    #                    differentiation_syndrome,
    #                    h360d_absent

if __name__ == "__main__":
    r = asyncio.run(scan_olutasidenib("1890397-31-3", 0.00041))
    print(r)
    # {'hd_category': 1, 'second_idh1_inhibitor': True,
    #  'idh1_two_nda_holder_class_null': True,
    #  'smallest_idh1_inhibitor_mw334': True,
    #  'allosteric_idh1_r132_dimer_interface': True,
    #  'cyp3a4_induction': True,
    #  'differentiation_syndrome': True,
    #  'h360d_absent': True}